Open-Label Safety Study of a 1-Year 20 mg Dose Regimen of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder (N24HSWD) in Blind Individuals With No Light Perception
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Adverse reactions; Registrational
- Sponsors Vanda Pharmaceuticals
- 01 Apr 2024 Planned End Date changed from 1 Dec 2018 to 5 Dec 2024.
- 01 Apr 2024 Planned primary completion date changed from 1 Dec 2018 to 5 Dec 2024.
- 01 Apr 2024 Status changed from recruiting to active, no longer recruiting.